CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitters ...
May 14 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to a ‌surgery, showed significantly improved survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results